Down-regulated VEGF expression in the diabetic heart is normalized by an endothelin ETA receptor antagonist.
Recently, down-regulation of vascular endothelial growth factor (VEGF) in the heart was suggested as a potential molecular explanation for the increased risk of cardiovascular morbidity and mortality in patients with diabetes. Increased endothelin-1 production is reported in diabetes. Here, we report that down-regulated VEGF expression in the diabetic rat heart is normalized by an endothelin ETA receptor antagonist, suggesting that endothelin antagonism may be a novel therapeutic strategy for diabetic heart.